Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
Clinical trial NCT05530057 · RECRUITING
Trial details
- NCT number
- NCT05530057
- Sponsor
- Seoul National University Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-18
- Primary completion
- 2028-06-30
- Enrollment
- 180
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.